Table of Contents Section 1: Introduction Section 1: Introduction Semaglutide, a medication initially approved for the treatment of type 2 diabetes, has gained attention for its potential benefits in weight management and cardiovascular health
KPV provides the anti-inflammatory peptide in capsule and spray formats
The dose increases by 0.25 mg each week for four weeks, then moves to maintenance levels of 1.72.4 mg weekly based on efficacy and tolerability
And the dose-dependent effects were clear: 4 mg, 8 mg, and 12 mg doses all produced escalating weight loss, with the highest dose delivering the most dramatic results
Durcan MJ, McWilliam JR, Campbell IC, Neale MC, Dunn G (1988)
With FDA approval for diabetes and chronic weight management, semaglutide offers a promising option for individuals looking to improve their health outcomes